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Abstract
Objectives To generate insight into the differences
between utility measures EuroQol 5D (EQ-5D), Health
Utilities Index Mark II (HUI2) and Mark III (HUI3) and
their impact on the incremental cost-effectiveness ratio
(ICER) for hearing aid ﬁtting
Methods Persons with hearing complaints completed
EQ-5D, HUI2 and HUI3 at baseline and, when applicable,
after hearing aid ﬁtting. Practicality, construct validity,
agreement, responsiveness and impact on the ICER were
examined.
Results All measures had high completion rates. HUI3
was capable of discriminating between clinically distinc-
tive groups. Utility scores (n = 315) for EQ-5D UK and
Dutch tariff (0.83; 0.86), HUI2 (0.77) and HUI3 (0.61)
were signiﬁcantly different, agreement was low to mod-
erate. Change after hearing aid ﬁtting (n = 70) for HUI2
(0.07) and HUI3 (0.12) was statistically signiﬁcant, unlike
the EQ-5D UK (0.01) and Dutch (0.00) tariff. ICERs varied
from e647,209/QALY for the EQ-5D Dutch tariff to
e15,811/QALY for HUI3.
Conclusion Utility scores, utility gain and ICERs heavily
depend on the measure that is used to elicit them. This
study indicates HUI3 as the instrument of ﬁrst choice when
measuring utility in a population with hearing complaints,
but emphasizes the importance of a clear notion of what
constitutes utility with regard to economic analyses.
Keywords Hearing loss  Costs and cost analysis 
Quality-adjusted life years  Questionnaires  Outcome
assessment (health care)
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Introduction
Hearing loss affects the ability to exchange information
and therefore affects a person’s quality of life [1]. Of the
western adult population, approximately 15% are hearing
impaired [2], and for these persons hearing aid use has
proven to be effective [3, 4]. The growth of the elderly
population has far-reaching implications for auditory
health service delivery and expenditure since the preva-
lence increases heavily with age. As a result, increasingly
more economic evaluations are undertaken on interven-
tions such as hearing aid ﬁtting. In economic evaluations
health related quality of life (HRQoL) should be measured
with a preference-based utility measure [5]. Until recently,
the beneﬁts of hearing aid ﬁtting had not translated into a
statistically signiﬁcant improvement in health state utility
[6–8]. In 2004 Barton et al [9] conﬁrmed this for the
EuroQol 5D (EQ-5D), but did ﬁnd statistically signiﬁcant
utility gain after hearing aid ﬁtting with the Health Utilities
Index Mark III (HUI3). This difference may result from
differences in the descriptive system, and the way the
scoring function is derived.
Also with regard to other conditions, a number of studies
have found that different utility measures tend to lead to
different utility scores [10–22]. In general there is need for
head-to-head comparisons of utility measures, in order to
assess the implications for the interpretation and compara-
bility of economic analyses, especially in conditions where
only subtle changes after treatment are expected [23, 24]. In
these comparisons the comparison of different tariffs should
also be incorporated. But most importantly, the impact of
the differences between measures on incremental cost-
effectiveness ratios (ICERs) should be made apparent.
Surprisingly, the latter has not yet received much attention.
The objective of this article is to compare the two most
frequently used utility measures in economic analyses [25]
in a Dutch population with hearing complaints. Utility
scores derived with the EQ-5D UK tariff [26], the EQ-5D
Dutch tariff [27], the Health Utilities Index Mark 2 (HUI2)
and HUI3 [28] are compared to generate further insight
into the differences between the measures, and the impact
on the ICER for hearing aid ﬁtting. In particular, this article
considers:
(1) practicality of using the EuroQol and HUI in a pop-
ulation with hearing complaints;
(2) construct validity of the EQ-5D UK tariff, EQ-5D
Dutch tariff, HUI2 and HUI3;
(3) agreement between the EQ-5D UK tariff, EQ-5D
Dutch tariff, HUI2 and HUI3;
(4) responsiveness of the EQ-5D UK tariff, EQ-5D Dutch
tariff, HUI2 and HUI3 after hearing aid ﬁtting;
(5) and the impact of on the ICER for hearing aid ﬁtting.
Methods
The EQ-5D, HUI2 and HUI3
The ﬁve questions of the EQ-5D descriptive system each
represent one dimension of health-related quality of life
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression) [29]. Each question has three levels
and the questions together classify persons into one of 243
health states. The commonly used scoring function is based
on a British study (EQ-5D UK tariff) [26], with preferences
derived with the time trade-off (TTO) method, in a repre-
sentative sample of the UK population of 2,997 respon-
dents. The scoring function is additive and the possible
range of utility scores is –0.59 to 1.00. Recently, Lamers
et al [27] developed a Dutch scoring function for the EQ-
5D (EQ-5D Dutch tariff), based on TTO in a sample of 298
respondents, with utility scores ranging from –0.33 to 1.00.
The 15 questions of the HUI descriptive system classify
respondents into either HUI2 or HUI3 health states. The
HUI system focuses on health ‘within the skin’, meaning
that they purely focus on impairment and not on the social
context of the impairment [28]. HUI2 consists of seven
attributes (sensation, mobility, emotion, cognition, self-
care, pain and fertility), with three to ﬁve levels, leading to
24,000 possible health states. The optional fertility attribute
was not used in the present study. The multiplicative
scoring function was derived using standard gamble (SG)
and Visual Analogue Scale (VAS) in a random sample of
293 Canadian respondents and utility scores range from –
0.03 to 1.00 [30]. HUI3 consists of eight attributes (vision,
hearing, speech, ambulation, dexterity, emotion, cognition
and pain), with ﬁve to six levels and leads to 972,000
possible health states. The multiplicative scoring function
was derived from SG and VAS, in a random sample of the
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sible utility scores varying from –0.36 to 1.00 [31].
Study population and data collection
Data were collected as part of a before-after study exam-
ining direct hearing aid provision versus provision by
referral [32]. The study was carried out in 2004–2005 in
three regions (Maastricht, Rotterdam and Amsterdam) in
the Netherlands. Persons with hearing complaints were
recruited from the participating Ear Nose and Throat
(ENT) departments, audiological centres and hearing aid
dispensers. Both EQ-5D and HUI were administered at the
ﬁrst visit to the ENT department. Questionnaires were
completed at the department, and respondents were helped
by a trained interviewer if requested. Patients who were
ﬁtted with a hearing aid were asked to attend the ENT
department for a follow-up visit to evaluate the hearing aid
ﬁtting. During the evaluation at the ENT department this
subset of patients completed both questionnaires for a
second time. Again, questionnaires were completed at the
department, and respondents were helped by a trained
interviewer if requested.
Practicality of the questionnaires
Especially in an elderly population, an important aspect
of a utility measure is the ease of completion. The
practicality of using the EQ-5D and the HUI in a
population with hearing complaints was therefore
assessed by the completion rate, using a Wilcoxon
Signed Ranks Test to test whether the completion rates
were signiﬁcantly different. Additionally we examined
the item non-response.
Construct validity
In absence of a gold standard to measure health state
utility, there is no clear technique to determine the con-
struct validity of utility measures. A way to examine the
construct validity is to examine whether utility scores are
different for distinctive groups [33, 34]. Other studies
have demonstrated differences of quality of life scores by
sex [33, 35, 36] and age [35–38]. Comparisons were
made between EQ-5D UK and Dutch tariff, HUI2 and
HUI3 scores by age (above versus below median) and
sex. It was expected that persons of a higher age and
females have lower utility scores. In addition, the
respondents were divided into ﬁve clinically distinctive
groups, based on their hearing loss and hearing aid use.
Hearing loss was deﬁned as the better ear pure tone
average (BEPTA) hearing loss for the frequencies 1000,
2000 and 4000 Hz. The groups were: persons who were
not entitled to reimbursement of a hearing aid (BEP-
TA < 35 dB); persons who were entitled to reimburse-
ment (BEPTA ‡ 35 dB) but did not apply for a hearing
aid (non-applicants); ﬁrst time hearing aid applicants;
experienced hearing aid users who were about to have a
new hearing aid ﬁtted (re-applicants); and experienced
hearing aid users who did not have a new hearing aid
ﬁtted.
It was expected that persons with a BEPTA smaller
than 35 dB would have a higher quality of life score than
persons in the other four groups, because they are likely
to experience less problems with hearing. It was also
expected that non-applicants had a higher utility score
than ﬁrst time applicants, since the latter group is ex-
pected to experience more hearing complaints, resulting
in ﬁtting a hearing aid as a solution for their hearing
problems.
Descriptive summary statistics were provided and nor-
mality was tested for all data using the Kolmogorov–
Smirnov test. Kruskal–Wallis one way ANOVA and
pairwise comparison tests (Mann–Whitney U) were used to
explore the differences between the groups.
Agreement
To assess agreement between the measures, a Wilcoxon
Signed-Rank test and a Paired t-test were used to test
whether the scores of the EQ-5D (UK and Dutch tariff),
HUI2 and HUI3 had the same distribution and mean.
Correlations (Kendall’s Tau) and the Intra-class Correla-
tion Coefﬁcient (ICC) were computed. The ICC was based
on a two-way mixed effect model, such that the subject
effect was random and the instrument effect was ﬁxed, and
computed at the individual patient level. An ICC below
0.75 implies poor to moderate agreement; above 0.75
implies good agreement [34].
Responsiveness
Responsiveness was tested in the subpopulation with a
valid score both before and after hearing aid ﬁtting. Effect
size and standardized response mean were calculated.
Effect size is the change in score divided by the standard
deviation of scores at baseline. Standardized response
mean is the change in score divided by the standard devi-
ation of the change in score. Both were interpreted using
benchmarks for effect size: 0.20 through 0.49 is interpreted
as small, 0.50 through 0.79 as moderate and ‡0.80 as large
[39]. Also, a Wilcoxon Signed Ranks Test and a Paired
t-test were conducted on the before and after scores. The
change in score after hearing aid ﬁtting was tested for
differences between ﬁrst time hearing aid applicants and
re-applicants. It was expected that re-applicants had a
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aid and therefore expectedly less hearing problems at
baseline.
Impact on the ICER
To illustrate the impact on the ICER, straightforward one
year ICERs of hearing aid ﬁtting versus no hearing aid
ﬁtting (doing nothing) were calculated. Quality Adjusted
Life Years (QALYs) were calculated using the area under
the curve method, for the EQ-5D (UK and Dutch tariff),
HUI2 and HUI3 [5]. Baseline utility scores were used to
estimate the effects of ‘no hearing aid ﬁtting’. Costs of no
hearing aid ﬁtting were assumed to be zero. This was
compared to the costs and effects after hearing aid ﬁtting.
The costs of hearing aid ﬁtting were calculated prospec-
tively for each respondent, including General Practitioner
(GP) visit(s), ENT visit(s) and hearing aid(s). We used
standard costs for medical consumption [40], and the actual
price of the hearing aid. As costs and utility scores are
generally not normally distributed, a non-parametric
bootstrap sampling method was used to calculate the 95%
conﬁdence interval around the ICERs [41]. Cost-effec-
tiveness acceptability curves for all measures were created
to characterize the likelihood that hearing aid ﬁtting will be
deemed cost-effective based on the incremental costs and
outcomes, for a range of ceiling ratios. Ceiling ratios
reﬂect societies’ maximum willingness to pay for a unit of
outcome.
Results
Practicality
Of the 337 persons with hearing complaints included in the
study, in total 315 (93%) fully completed both the EQ-5D
and the HUI descriptive system at baseline. Each item on
the EQ-5D had six missing values, except for mobility
(n = 5). Regarding the HUI, all questions had six or seven
missing values, except for the questions on hearing in a
group conversation (n = 12), pain and discomfort (n = 10),
and hearing in a conversation with one other person
(n = 8). Although completion rates were high for both
questionnaires, EQ-5D was fully completed by 328 persons
(97%), which is signiﬁcantly more than the 318 persons
(94%) who completed the HUI (P-value 0.012).
Of the 315 persons who completed both EQ-5D and
HUI at baseline, 173 persons (55%) had a hearing aid ﬁt-
ted. Of them, 82 (47%) attended the ENT department for
the follow-up visit after hearing aid ﬁtting. Ninety-one
respondents (53%) who had a hearing aid ﬁtted did not
show at the follow-up visit because they had not ﬁnished
their hearing aid ﬁtting before the end of the study
(n = 37), or because they had a hearing aid ﬁtted at a
dispenser not participating in the study (n = 54), and were
therefore lost to follow up. Of the 82 respondents who did
attend the follow-up visit, 70 (85%) fully completed both
the EQ-5D and HUI descriptive system. Each item on the
EQ-5D had ﬁve missing values, except for pain/discomfort
(n = 6). Regarding the HUI, the hearing questions both had
four missing values, and the other questions had four to
seven missing values. Seventy-six persons (93%) fully
completed the EQ-5D, while 71 persons (87%) fully
completed the HUI. This difference is not statistically
signiﬁcant (P-value 0.059).
Construct validity
Mean age of the respondents was 69.6 years (sd 8.9;
median 70), and BEPTA was on average 42 dB. The
respondents were divided into groups below 70 years old
(n = 156) versus 70 years and older (n = 159) and male
(n = 189) versus female (n = 126), see Table 1. The scores
on the EQ-5D, HUI2 and HUI3 were not normally dis-
tributed (Kolmogorov–Smirnov test, P-value 0.000). Only
the EQ-5D detected differences in reported health by both
age and sex. HUI3 detected a difference in utility between
the age groups, HUI2 did not detect any differences.
Furthermore, the respondents were divided into ﬁve
clinically distinctive groups: BEPTA < 35 dB (n = 69),
non-applicants (n = 46), ﬁrst time hearing aid applicants
(n = 108), re-applicants (n = 65), and experienced hearing
aid users not applying for a new hearing aid (n = 12). The
latter group was excluded from the analysis because of the
small sample size. Fifteen persons could not be classiﬁed
into a clinical group because they were lost to follow-up
after the ﬁrst visit.
Based on the EQ-5D and HUI2, no distinction could be
made between any of the clinically distinctive groups. A
logarithmic transformation was performed on the EQ-5D
and HUI2 data to compensate for skewness. Even after
transformation, and also when correcting for age, sex and
BEPTA, no differences were found between the groups.
Only HUI3 scores demonstrated a signiﬁcant difference
between the clinically distinctive groups (Kruskall–Wallis;
P-value 0.004). More speciﬁcally, HUI3 found signiﬁcant
differences between persons with a BEPTA < 35 dB and
ﬁrst time applicants (Mann–Whitney U; P-value 0.002),
and between persons with a BEPTA < 35 dB and
re-applicants (P-value 0.001). HUI3 did not conﬁrm our
expectation that non-applicants had signiﬁcantly higher
utility scores than ﬁrst time applicants. As expected,
non-applicants stated less problems on the hearing attribute
than ﬁrst time applicants, but they also stated more prob-
lems on the ambulation and pain attributes.
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A summary of the utility scores is presented in Table 2.
Mean utility scores for the population with hearing com-
plaints were higher for the EQ-5D Dutch tariff (mean 0.86;
standard deviation 0.18) and EQ-5D UK tariff (0.83; sd
0.21) than for the HUI2 (0.77; sd 0.14) and HUI3 (0.61; sd
0.24). The differences in mean scores and distributions are
statistically signiﬁcant. The UK and Dutch tariff of the
EQ-5D and HUI2 and HUI3 were found to have good
agreement, since they were strongly correlated (0.90; 0.71)
and had an ICC of 0.98 and 0.74, respectively. The scores
on all other measures showed statistically signiﬁcant, but
low correlations and their agreement was moderate to poor
(Table 3).
Ceiling effects were observed in the EQ-5D UK tariff
(Figs. 1 and 2), results were similar for EQ-5D Dutch
tariff. As measured with the EQ-5D (both UK and Dutch
tariff), 44% of the respondents reported perfect health,
despite their hearing complaints. Measured with the HUI2
or HUI3, less than 1% of the respondents reported perfect
health. For respondents reporting perfect health on the
EQ-5D, mean utility scores were 0.83 on the HUI2 (range
0.35–1.00) and 0.71 on the HUI3 (range 0.06–1.00).
Responsiveness
Responsiveness was tested in the subpopulation with a
valid score both before and after hearing aid ﬁtting
(n = 70). The effect size and standardized response mean
of the EQ-5D UK (0.05; 0.05) and Dutch tariff (0.03; 0.02)
were less than small. HUI2 and HUI3 were more respon-
sive to change after hearing aid ﬁtting, since both had a
moderate effect size (0.64; 0.55) and standardized response
mean (0.57; 0.66).
Mean change in utility after hearing aid ﬁtting (Table 4)
was highest when measured with the HUI3 (mean 0.12; sd
0.18) and HUI2 (0.07; sd 0.13), while almost no change
was measured with the EQ-5D (UK tariff 0.01, sd 0.13;
Dutch tariff 0.00, sd 0.12). The change in utility measured
with HUI2 and HUI3 is statistically signiﬁcant (Paired
t-test, P-values 0.005 and 0.000). No change was observed
in any attribute of the EQ-5D (Fig. 3a). The change in
HUI2 utility score after hearing aid ﬁtting occurred in the
sensation attribute (Fig. 3b) and in the HUI3 score in the
hearing attribute (Fig. 3c). Almost no change was observed
in any of the other attributes of the HUI2 and HUI3.
The mean change in utility score after hearing aid ﬁt-
ting, when measured with HUI2 and HUI3, was higher for
ﬁrst-time hearing aid applicants (0.08; 0.13) than for
re-applicants (0.06; 0.10). This outcome was in line with
our expectations, but is not signiﬁcantly different.
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Mean costs of doing nothing were zero. The mean costs
of hearing aid ﬁtting were e1,877. The latter consisted
of GP visits (e37), ENT visits (e295) and hearing
aid(s) (e1545). All hearing aids were digital, and
hearing aids were bilaterally ﬁtted in 83% of the
respondents.
This resulted in mean one-year incremental costs of
hearing aid ﬁtting versus doing nothing of e1,877. The
mean utility gain of 0.01 (sd 0.13), measured with the
EQ-5D UK tariff, resulted in a ratio of e286,866 per
QALY, with a 95% conﬁdence interval of inferior
(higher costs, lower utility) to e47,082/QALY. There
was a 36% probability that hearing aid ﬁtting was both
more costly and less effective (inferior). The mean utility
Table 3 Agreement in the baseline population with hearing complaints (n = 315)
Pairs of utility functions Kendall’s Tau* ICC (95% Conﬁdence interval)
EQ-5D UK tariff versus HUI2 r = 0.41 0.51 (0.42–0.59)
EQ-5D UK tariff versus HUI3 r = 0.37 0.47 (0.38–0.55)
EQ-5D UK versus Dutch tariff r = 0.90 0.98 (0.97–0.98)
HUI2 versus HUI3 r = 0.71 0.74 (0.68–0.78)
HUI2 versus EQ-5D Dutch tariff r = 0.40 0.51 (0.42–0.59)
HUI3 versus EQ-5D Dutch tariff r = 0.36 0.44 (0.35–0.53)
* All statistically signiﬁcant, P < 0.01
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Fig. 2 Scatterplot of utility scores derived with EQ-5D UK tariff and
HUI3
Table 2 Utility scores in baseline population with hearing complaints (n = 315)
Measure Minimum Maximum Median* Interquartile range Mean** Standard deviation
EQ-5D UK tariff –0.25 1.00 0.85 0.27 0.83 0.21
EQ-5D Dutch tariff –0.03 1.00 0.86 0.19 0.86 0.18
HUI2 0.23 1.00 0.79 0.15 0.77 0.14
HUI3 –0.07 1.00 0.62 0.38 0.61 0.24
* All statistically signiﬁcantly different: Wilcoxon Signed-Rank test; P < 0.01
** All statistically signiﬁcantly different: Paired t-test; P < 0.01
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123gain of 0.003, measured with the EQ-5D Dutch tariff,
resulted in an ICER of e647,209 per QALY (95%
conﬁdence interval: inferior to e61,934/QALY). There
was a 42% probability that hearing aid ﬁtting was
inferior. Applying the HUI2 and HUI3, the ICER was
e25,337 per QALY (95% conﬁdence interval: e38,012/
Table 4 Change in health state utility after hearing aid ﬁtting and ICER with 95% Conﬁdence Interval (CI) (n = 70)
Measure Mean Standard
deviation
Median Interquartile
range
Minimum Maximum ICER
a e/
QALY
(95% CI)
e/QALY
EQ-5D UK tariff 0.01 0.13 0.00 0.04 –0.60 0.27 286,866 (inferior
b–47,082)
EQ-5D Dutch
tariff
0.00 0.12 0.00 0.04 –0.60 0.28 647,209 (inferior
b–61,934)
HUI2 0.07* 0.13 0.08** 0.12 –0.50 0.40 25,337 (19,356–38,012)
HUI3 0.12* 0.18 0.13** 0.22 –0.22 0.60 15,811 (11,664–24,654)
* Statistically signiﬁcant; Paired t-test; P < 0.01
** Statistically signiﬁcant: Wilcoxon Signed-Rank test; P < 0.01
a ICER based on mean scores
b Inferior means higher costs and lower utility
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123QALY to e19,356/QALY) and e15,811 per QALY
(95% conﬁdence interval: e24,654/QALY to e11,664/
QALY) respectively. For both measures there was no
probability that hearing aid ﬁtting was inferior.
The informal Dutch ceiling ratio of e20,000/QALY
[42] implied that hearing aid ﬁtting was only cost-effective
when utility was measured with the HUI3. A cost-
effectiveness plane with incremental cost and effect pairs
for 1,000 bootstrap replications, for all measures, is shown
in Fig. 4. Figure 5 shows the cost-effectiveness accept-
ability curves for all measures.
Conclusion and discussion
Hearing loss affects the exchange of information and
therefore affects a person’s quality of life [1]. Hearing
impaired persons can beneﬁt from using a hearing aid,
since hearing aid use has proven to be effective, it
improves social, emotional and communication functions
and reduces depression [3, 4].
The results of this study in a relatively healthy popula-
tion with hearing complaints provide insight in the differ-
ences between two widely used utility measures, the
EQ-5D and the HUI system.
Regarding practicality, both questionnaires had high
completion rates, with the EQ-5D having a higher com-
pletion rate than the HUI.
With the EQ-5D, differences were detected in utility by
age and sex, indicating construct validity. The HUI3
detected differences by age, but not by sex. Differences
between clinically distinctive groups were only detected by
HUI3. However, the HUI3 did not conﬁrm our expectation
that non-applicants would have higher utility values than
ﬁrst-time applicants. An explanation for this may be that
non-applicants had more health problems other than their
hearing, as reﬂected in the ambulation and pain dimensions
of the HUI3.
Overall, HUI2 and HUI3 scores were lower than EQ-5D
scores and agreement was moderate to poor. Although
these measures intend to assess the same construct, namely
health state utility, this result was expected as the instru-
ments differ in their underlying assumptions about what
constitutes health state utility.
As to responsiveness, only HUI2 and HUI3 measured
statistically signiﬁcant improvement after hearing aid ﬁt-
ting, the EQ-5D UK and Dutch tariff both were not able to
capture this effect. Half of the patients (53%) who were
ﬁtted with a hearing aid were lost to follow up, either
because they had not ﬁnished their hearing aid ﬁtting
before the end of the study, or because they had their
hearing aid ﬁtted at a dispenser not participating in our
study. As these patients did not differ from the follow-up
group in baseline utility, hearing loss and age, we did not
expect this low response rate to inﬂuence the results.
The HUI2 and HUI3 change scores resulted in smaller
ICERs for hearing aid ﬁtting. Although they were only
illustrative, the different ICERs found in the present study
clearly show that the choice of a utility instrument in the
economic evaluation of hearing aid ﬁtting may heavily
inﬂuence the cost-effectiveness outcome.
To calculate the ICER of hearing aid ﬁtting we included
the total population of respondents considered for hearing
aid ﬁtting, regardless of the type of hearing aid ﬁtting. This
makes the ICERs found in the present study representative
for hearing aid ﬁtting in general in the Netherlands.
However, the one year ICERs calculated in the present
study were merely illustrative of the impact of different
utility scores on the ICER of hearing aid ﬁtting, as the cost-
effectiveness of hearing aid ﬁtting has thoroughly been
examined by Joore et al [8].
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123Our results conﬁrm Barton et al [9, 43], who compared
the EQ-5D UK tariff and HUI3 before and after hearing aid
ﬁtting in a UK sample. However, the change in utility after
hearing aid ﬁtting derived with the HUI3 in the present
study was twice the change in utility derived with the HUI3
in the study of Barton et al [9]. Respondents in the latter
study had a lower baseline utility score and a higher range
in utility change after hearing aid ﬁtting, which suggests a
somewhat different study population. Our results conﬁrm
previous studies that concluded that the EQ-5D lacks suf-
ﬁcient sensitivity to measure the beneﬁt of hearing aid
ﬁtting [6, 7, 44]. The lower utility scores and higher
responsiveness of the HUI3 in relation to the EQ-5D were
also found in a population with visual impairment [22].
Joore et al [8] calculated that hearing aid ﬁtting costs
e15,807 per QALY, using the EQ-5D as utility measure.
The results of the present study indicate that using the
HUI3 as utility measure probably had resulted in a more
favourable ICER for hearing aid ﬁtting. Vuorialho et al
[45] recently concluded that counseling of hearing aid
users to reduce the number of non-users is highly cost-
effective, although they were unable to measure any
change in utility. As they used the EQ-5D, it is possible
that they would have been able to demonstrate favourable
costs per QALY when they would have used the HUI3 to
measure change in utility.
Three questions arise from the results of the present
study: can differences be explained by differences in the
measures, are the differences observed between the mea-
sures important, and what are the implications of the
ﬁndings for utility measurement and cost-utility analysis in
populations with hearing complaints?
First, differences in utility scores can be explained by
differences in the descriptive system and the way the utility
scoring function is derived. Regarding the descriptive
system, the focus of the EQ-5D on physical, mental and
social functioning [46] differs from the ‘within-the-skin’
perspective of HUI, which focuses on the underlying level
of impairment. However, this does not explain why the
EQ-5D does not measure change after hearing aid ﬁtting, as
previous studies have found that hearing aid ﬁtting
improves social and emotional functioning [3, 4]. Also, the
measures differ in the content and number of attributes,
items and levels used, and therefore differ both in the
number and in the content of possible health states. It has
already been suggested not to use the EQ-5D in relatively
healthy populations, given the presence of a ceiling effect
[15]. The ceiling effect of the EQ-5D found in the present
study is likely to contribute to the differences in respon-
siveness. When, as found in our study, 44% of the
respondents report perfect health at baseline, it is unlikely
to ﬁnd a considerable utility gain from any intervention.
Furthermore, since the HUI descriptive system pays
explicit attention to hearing abilities, it is to be expected
that in a relatively healthy population with hearing com-
plaints HUI and EQ-5D utility scores differ, and HUI is
more responsive. As the HUI3 also pays explicit attention
to visual abilities, this may explain why comparisons of
EQ-5D and HUI3 in hearing and vision show similar
results [22].
There are also differences in the utility scoring func-
tions. Although in general SG (used for HUI) leads to
higher scores than TTO (used for EQ-5D) [5], in the
present study the EQ-5D scores were considerably higher
than the HUI scores. Although different populations do not
necessarily yield different results [5], the population sam-
ple in which the preferences are measured may also have
impact on the differences. In the present study, differences
between utilities derived with the UK and Dutch tariff were
observed. This difference may be the result of differences
in health valuation between people from the Netherlands
and the UK, but may also result from the somewhat
questionable representativeness of the population sample
used to develop the Dutch tariff [27].
Differences also exist in the type of scoring function.
EQ-5D uses an additive system, assuming no interaction
for preferences among attributes at all. The HUI uses a
multiplicative scoring function, with the effect that the loss
of utility associated with a particular dimension is depen-
dent on the level of impairment on other dimensions [5].
For example, Barton et al [43] illustrated that hearing
impairment (‘unable to hear at all’) has a greater impact on
HRQoL as measured with the HUI3 when one has no other
health problems (–0.53), than when one also has moderate
to severe pain and is unable to see at all (–0.05). It seems
rational that persons ﬁnd their hearing loss a less important
aspect of their health state utility when they experience
more comorbidity. The multiplicative scoring function of
HUI takes this inﬂuence of comorbidity into account and
seems to be more suitable for modeling utility scores.
Are the differences observed between the measures
important? The answer to this question is a clear ‘yes’. The
impact of different utility measures on the ICER for
hearing aid ﬁtting is of a magnitude that can alter policy
decisions and emphasizes that comparisons of QALYs
across studies and interventions should be interpreted with
caution [12]. The general purpose of a utility measure is to
capture the health effects in terms of HRQoL of a policy or
program for use in economic analyses. Health economic
analyses are a tool to allocate resources in a way that
maximizes health (or welfare). In order to use the outcomes
of economic analyses for policy decisions, there should
however be a clear notion of what should be maximized.
The results of the present study show that the potential
beneﬁt of an intervention heavily depends on the assump-
tions of what constitutes health underlying the utility
Qual Life Res (2007) 16:1439–1449 1447
123measure that is used. Beyond the apparent necessity of
psychometric quality of a utility measure, an important
area for future research is whether societies wish, or
should, maximize life expectancy corrected for HRQoL
from a more functional perspective as in the EQ-5D, or
from a ‘within-the-skin’ perspective as in the HUI. Other
studies that have thoroughly examined the psychometric
differences between utility measures seem to pass over this
important question [11, 13, 19, 21, 24].
What are the implications of the ﬁndings for utility
measurement and cost-utility analysis in populations with
hearing complaints? Generally, it has been recommended
that the instrument that is most sensitive to the health states
in which one is interested should be selected [5, 12, 47].
From clinical experience it is plain that hearing aid use is
effective in alleviating hearing loss and does improve
health-related quality of life, but the EQ-5D lacks the
sensitivity to capture this improvement. In an otherwise
healthy population, HUI3 has proven to be more responsive
and therefore more appropriate for evaluating HRQoL in a
population with hearing complaints, and is therefore the
instrument of ﬁrst choice in this population.
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